Clinical Trials Logo

Peanut Allergy clinical trials

View clinical trials related to Peanut Allergy.

Filter by:

NCT ID: NCT03648320 Completed - Peanut Allergy Clinical Trials

The Grown Up Peanut Immunotherapy Study

GUPI
Start date: October 15, 2018
Phase: N/A
Study type: Interventional

To determine efficacy and safety of peanut oral immunotherapy in adults with peanut allergy.

NCT ID: NCT03546413 Completed - Peanut Allergy Clinical Trials

Follow up of LEAP Participants and Their Families

Start date: July 5, 2018
Phase:
Study type: Observational

This prospective, cross-sectional study was designed to improve understanding of how early-life introduction of peanuts may promote the maintenance of tolerance in adolescence and will serve as an additional safety evaluation of the original nutritional intervention.

NCT ID: NCT03532360 Active, not recruiting - Peanut Allergy Clinical Trials

Peanut and Tree Nut Desensitization

Start date: February 19, 2018
Phase: N/A
Study type: Interventional

this study evaluates whether tolerance to peanuts and tree nuts can be induced in patients through a process of oral immunotherapy. Participants will be randomized into groups receiving oral immunotherapy and a control group that will receive no intervention

NCT ID: NCT03513965 Completed - Peanut Allergy Clinical Trials

Allergy Experience Study

Start date: January 5, 2017
Phase: N/A
Study type: Interventional

People who are undergoing oral immunotherapy for food allergy treatment can feel anxious about the treatment process, particularly when they have allergic responses (e.g., hives, vomiting, nausea) during the dosing process. People may commonly believe that these symptoms are simply side effects that must be endured or avoided. However, the investigators propose that changing participants' mindsets about the meaning of symptoms—toward viewing them as a sign that the treatment is working and desensitization is increasing—during the treatment process will reduce anxiety and improve treatment outcomes.

NCT ID: NCT03352726 Completed - Peanut Allergy Clinical Trials

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

V712-103
Start date: November 24, 2017
Phase: Phase 1
Study type: Interventional

The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.

NCT ID: NCT03337542 Completed - Peanut Allergy Clinical Trials

AR101 Real-World Open-Label Extension Study

Start date: October 18, 2017
Phase: Phase 3
Study type: Interventional

This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.

NCT ID: NCT03292484 Completed - Peanut Allergy Clinical Trials

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Start date: October 11, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.

NCT ID: NCT03251508 Completed - Peanut Allergy Clinical Trials

Salvage Peanut Oral Immunotherapy Study

SOIT
Start date: January 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to study the safety of rescue peanut oral immunotherapy followed by the introduction of dietary peanut for patients with peanut allergy who have lost desensitization during a peanut immunotherapy trial.

NCT ID: NCT03211247 Active, not recruiting - Peanut Allergy Clinical Trials

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

EPITOPE
Start date: July 31, 2017
Phase: Phase 3
Study type: Interventional

The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).

NCT ID: NCT03201003 Completed - Peanut Allergy Clinical Trials

ARTEMIS Peanut Allergy In Children

ARTEMIS
Start date: June 12, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.